ES2183206T3 - Uso de hialuronidasa. - Google Patents
Uso de hialuronidasa.Info
- Publication number
- ES2183206T3 ES2183206T3 ES97934835T ES97934835T ES2183206T3 ES 2183206 T3 ES2183206 T3 ES 2183206T3 ES 97934835 T ES97934835 T ES 97934835T ES 97934835 T ES97934835 T ES 97934835T ES 2183206 T3 ES2183206 T3 ES 2183206T3
- Authority
- ES
- Spain
- Prior art keywords
- hyaluronidase
- hyaluronan
- mammal
- connection
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract 3
- 102000001974 Hyaluronidases Human genes 0.000 abstract 3
- 229960002773 hyaluronidase Drugs 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010030113 Oedema Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 2
- 229940099552 hyaluronan Drugs 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
UTILIZACION DE HIALURONIDASA EN LA PREPARACION DE UN MEDICAMENTO QUE SIRVE PARA TRATAR UN ESTADO DE EDEMA INTERSTICIAL QUE PROCEDE DE UN INJERTO DE UN ORGANO ASOCIADO CON UN AUMENTO DE LA CANTIDAD LOCAL DE HIALURONIDASA EN EL TEJIDO CONJUNTIVO DE UN MAMIFERO. ESTE MEDICAMENTO CONTIENE UNA CANTIDAD DE HIALURONIDASA QUE PERMITE UNA DOSIFICACION DIARIA DE 1 A 1.000.000 IU/KG DE PESO DEL CUERPO CUANDO SE ADMINISTRA A LOS MAMIFEROS DE MANERA LOCAL O SISTEMICA. ESTE PROCEDIMIENTO SIRVE PARA TRATAR ESTADOS EDEMICOS INTERSTICIALES QUE PROCEDEN DE UN INJERTO DE UN ORGANO ASOCIADO CON UN AUMENTO DE LA SINTESIS LOCAL DE HIALURONIDASA MEDIANTE UN TRATAMIENTO LOCAL O SISTEMICO MEDIANTE UN MEDICAMENTO FARMACEUTICO QUE CONTIENE HIALURONIDASA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9603082A SE509350C2 (sv) | 1996-08-26 | 1996-08-26 | Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2183206T3 true ES2183206T3 (es) | 2003-03-16 |
Family
ID=20403654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97934835T Expired - Lifetime ES2183206T3 (es) | 1996-08-26 | 1997-07-24 | Uso de hialuronidasa. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0942745B1 (es) |
| JP (1) | JP4087453B2 (es) |
| AT (1) | ATE224729T1 (es) |
| AU (1) | AU721141B2 (es) |
| CA (1) | CA2262637C (es) |
| DE (1) | DE69715898T2 (es) |
| ES (1) | ES2183206T3 (es) |
| NO (1) | NO325945B1 (es) |
| SE (1) | SE509350C2 (es) |
| WO (1) | WO1998008538A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2177227B1 (en) | 2008-10-14 | 2013-03-20 | Burgard, Gunter, Dr. med. | Use of hyaluronidase for the prevention or treatment of arterial hypertension. |
| EP2392325A1 (en) | 2010-06-04 | 2011-12-07 | Universitätsklinikum Münster | Compounds for the prevention and/or treatment of osteoarthrosis |
-
1996
- 1996-08-26 SE SE9603082A patent/SE509350C2/sv not_active IP Right Cessation
-
1997
- 1997-07-24 CA CA002262637A patent/CA2262637C/en not_active Expired - Fee Related
- 1997-07-24 AT AT97934835T patent/ATE224729T1/de not_active IP Right Cessation
- 1997-07-24 JP JP51152798A patent/JP4087453B2/ja not_active Expired - Fee Related
- 1997-07-24 DE DE69715898T patent/DE69715898T2/de not_active Expired - Lifetime
- 1997-07-24 WO PCT/SE1997/001313 patent/WO1998008538A1/en not_active Ceased
- 1997-07-24 AU AU37908/97A patent/AU721141B2/en not_active Ceased
- 1997-07-24 EP EP97934835A patent/EP0942745B1/en not_active Expired - Lifetime
- 1997-07-24 ES ES97934835T patent/ES2183206T3/es not_active Expired - Lifetime
-
1999
- 1999-02-25 NO NO19990898A patent/NO325945B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO325945B1 (no) | 2008-08-25 |
| WO1998008538A1 (en) | 1998-03-05 |
| EP0942745B1 (en) | 2002-09-25 |
| AU3790897A (en) | 1998-03-19 |
| ATE224729T1 (de) | 2002-10-15 |
| SE9603082D0 (sv) | 1996-08-26 |
| AU721141B2 (en) | 2000-06-22 |
| EP0942745A1 (en) | 1999-09-22 |
| NO990898L (no) | 1999-02-25 |
| DE69715898D1 (de) | 2002-10-31 |
| SE509350C2 (sv) | 1999-01-18 |
| NO990898D0 (no) | 1999-02-25 |
| SE9603082L (sv) | 1998-02-27 |
| JP4087453B2 (ja) | 2008-05-21 |
| JP2000517315A (ja) | 2000-12-26 |
| DE69715898T2 (de) | 2004-01-22 |
| CA2262637C (en) | 2004-03-30 |
| CA2262637A1 (en) | 1998-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9800467A3 (en) | Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis | |
| EP0933995B8 (en) | Method of treating endothelial injury | |
| EP1248613A4 (en) | CLONIDINE PREPARATIONS | |
| CA2301057A1 (en) | A method of administering liposomal encapsulated taxane | |
| MX9702349A (es) | Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma. | |
| NO962088L (no) | Preparat for in vivo-produksjon av terapeutiske produkter | |
| PL323490A1 (en) | Tetralinic compounds exibiting acitity against multgiple-drug refractoriness | |
| DK0785769T3 (da) | Terapeutisk vitamin-calcium-kombination i form af en galenisk enhedsdosistablet, fremgangsmåde til fremstilling af denne sa | |
| ES2154693T3 (es) | Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias. | |
| AU1534699A (en) | Osmotic dosage form comprising first and second coats | |
| IL132115A0 (en) | Drug preparations for treating sexual dysfunction | |
| IT1264530B (it) | Impiego dei polisaccaridi nelle neuropatie atrofico degenerative | |
| GR3034575T3 (en) | Steroid nitrite ester derivatives useful as anti-inflammatory drugs | |
| EP0974363A4 (en) | REMEDIES FOR ADDICTION | |
| ITMI992107A0 (it) | Uso del baclofen nel trattamento dell'astinenza da etanolo | |
| EP0429522A4 (en) | Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs | |
| BG102342A (en) | Optical active derivative of phenylpyrimidine as an anlgesics | |
| SE9603082D0 (sv) | Use of hyaluronidase | |
| AU2693697A (en) | Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin | |
| AU5691796A (en) | Terpenoidic derivatives useful as antitumor agents | |
| EP0971725A4 (en) | METHOD FOR TREATING SCAR TISSUE | |
| CA2234936A1 (en) | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine | |
| NO20000098D0 (no) | Anvendelse av hyaluronidase ved fremstillingen av et medikament for behandling av inflammasjon | |
| RU95122486A (ru) | Средство для лечения тикозных гиперкинезов | |
| NZ336633A (en) | The use of chitosans for the production of antithrush formulations |